Eponyms in Oncology: HeLa cells
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of HeLa cells.
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of HeLa cells.
The highest rate of non-concordant care was seen in patients with cervical cancer.
About 63% of patients were diagnosed with stage II or higher disease.
The approval was based on data from the phase 2 innovaTV 204 trial that evaluated Tivdak as monotherapy in 101 adult females with recurrent or metastatic cervical cancer.
Researchers analyzed recent trends in cervical cancer incidence and mortality and made predictions for the next 15 years.
For HPV-related cancers without standardized screening, incidence rates increased between 2001 and 2017.
New guidelines from the American Cancer Society (ACS) appear to move away from the reliance on cytology screening via Pap testing.
The consensus guideline, drafted by an ASTRO-convened expert task force, offers recommendations about radiotherapy, including brachytherapy, and chemoradiation, in different stage-of-disease and treatment-strategy settings.
The US Preventive Services Task Force recommends cervical cancer screening with cervical cytology alone every 3 years or screening with high-risk human papillomavirus testing alone every 5 years.
While more teenagers are now starting the HPV vaccination dose cycle, many still aren’t completing the full series.